Abstract
Helicobacter pylori is a helical shaped Gram-negative bacterium that colonizes the human stomach. It is associated with several human pathologies, such as gastritis, peptic ulcer, and gastric cancer. The standard first-line treatment is a one week triple therapy: the association of two antibiotics, most frequently amoxicillin and clarithromycin, and a proton pump inhibior. Despite the evolution of the treatment strategy, quadruple therapy, there is an increasing percentage of failure of the antibiotic therapy, due to antibiotics resistance. Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections and H. pylori is a good target. However there are no available phage collections, and H. pylori phages description is diminutive on literature.
| Original language | English |
|---|---|
| Pages (from-to) | 150-151 |
| Number of pages | 2 |
| Journal | Microscopy and Microanalysis |
| Volume | 14 |
| Issue number | SUPPL. 3 |
| DOIs | |
| Publication status | Published - Sept 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Helicobacter pylori phage screening'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver